Covaxin, the vaccine manufactured by Bharat Biotech, has demonstrated overall interim clinical efficacy of 78 per cent, and 100 per cent efficacy against severe Covid-19 disease in phase 3 trials, the company and Indian Council of Medical Research (ICMR) announced on Wednesday.
Explained: What phase 3 data says on Bharat Biotech’s Covaxin vaccine
COVAXIN capable of neutralising UK, double mutant strains, says ICMR: Implications of the study, explained
2-4 per 10,000 people infected after getting vaccinated, Covaxin works against mutant viruses: govt
Both Covishield & Covaxin work, only 3-4 in 10,000 infected post vaccine, Modi govt releases data
Bharat Biotech’s Covaxin 78% effective; works against most COVID-19 variants